Loading…
KENGREXAL is a brand name for Cangrelor, supplied as a powder for solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: KENGREXAL (cangrelor) is indicated for reducing the risk of thrombotic cardiovascular events (periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST)) in patients with coronary artery disease undergoing percutaneous coronary intervention who have not been treated with an…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations • KENGREXAL is intended for intravenous injection or infusion only, in an acute and hospital setting Transitioning Patients to Oral P2Y12 Therapy To maintain platelet inhibition after discontinuation of KENGREXAL infusion, administer an oral P2Y12 platelet inhibitor, as described below: • Ticagrelor: 180 mg immediately after discontinuation of KENGREXAL (see 9 DRUG INTERACTIONS and 10 CLINICAL PHARMACOLOGY).
• Prasugrel: 60 mg immediately after discontinuation of KENGREXAL. Do not administer prasugrel prior to discontinuation of KENGREXAL (see 9 DRUG INTERACTIONS and 10 CLINICAL PHARMACOLOGY). • Clopidogrel: 600 mg immediately after discontinuation of KENGREXAL.
Do not administer clopidogrel prior to discontinuation of KENGREXAL (see 9 DRUG INTERACTIONS and 10 CLINICAL PHARMACOLOGY). 2 Recommended Dose and Dosage Adjustment • The recommended dosage of KENGREXAL is a 30 μg/kg IV bolus followed immediately by a 4 μg/kg/min IV infusion.
Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer. The infusion may be continued for maximal duration of 4 hours. • No dosage adjustment is required for patients with mild, moderate, or severe renal impairment (see 10 CLINICAL PHARMACOLOGY).
• KENGREXAL has not been studied in patients with hepatic impairment. The metabolism of KENGREXAL is not dependent of hepatic function, so dosage adjustment is not expected to be required for patients with hepatic impairment (see 10 CLINICAL PHARMACOLOGY).
1 Pediatrics). • Geriatrics (≥75 years of age): No dose adjustment is needed in older patients. 3 Reconstitution KENGREXAL is intended for IV administration, after reconstitution and dilution. Aseptic procedures should be used for the preparation of KENGREXAL.
Preparation Reconstitute the vial prior to dilution in a bag. For each 50 mg/vial, reconstitute by adding 5 mL of Sterile Water for Injection (see Table 1). Swirl gently until all material is dissolved. Avoid vigorous mixing. Allow any foam to settle.
Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colourless to pale yellow solution. Parenteral drug products should be inspected visually for particulate matter after reconstitution.
). • patients who had an ischemic stroke or any previous hemorrhagic stroke. , anaphylaxis) to KENGREXAL or any component of the product, including any non-medicinal ingredient or component of the container (see 8 ADVERSE REACTIONS).
For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. 1 Dosing Considerations • KENGREXAL is intended for intravenous injection or infusion only, in an acute and hospital setting Transitioning Patients to Oral P2Y12 Therapy To maintain platelet inhibition after discontinuation of KENGREXAL infusion, administer an oral P2Y12 platelet inhibitor, as described below: • Ticagrelor: 180 mg immediately after discontinuation of KENGREXAL (see
KENGREXAL is contraindicated in: • patients with significant active bleeding or an increased risk of bleeding (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS). • patients who had an ischemic stroke or any previous hemorrhagic stroke.
, anaphylaxis) to KENGREXAL or any component of the product, including any non-medicinal ingredient or component of the container (see 8 ADVERSE REACTIONS). For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
9% USP) or 5% Dextrose Injection USP. Withdraw the contents from one reconstituted vial and add to one 250 mL saline bag. Mix the bag thoroughly. This dilution will result in a concentration of 200 μg/mL and should be sufficient for at least 2 hours of dosing.
Patients 100 kg and over will require a minimum of two bags. Reconstituted KENGREXAL should be diluted immediately. Diluted KENGREXAL is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in normal saline at room temperature.
Discard any unused portion of reconstituted solution remaining in the vial. 4 Administration Administer KENGREXAL in a dedicated IV line. Administer the bolus volume rapidly (<1 minute) from the diluted bag via manual IV push or pump.
Ensure bolus is completely administered before the start of PCI. Start the infusion immediately after administration of the bolus (see 4 DOSAGE AND ADMINISTRATION). 5 Missed Dose Not applicable.